Instem shares soar following US government contract win

Shares in Instem leapt by a third on Thursday after the software provider revealed that the National Institute of Environmental Health Sciences (NIEHS) has purchased its Provantis 9 preclinical software suite via SaaS [Software-as-a-Service] to support National Toxicology Programme (NTP) studies.

Shares in Instem leapt by a third on Thursday after the software provider revealed that the National Institute of Environmental Health Sciences (NIEHS) has purchased its Provantis 9 preclinical software suite via SaaS [Software-as-a-Service] to support National Toxicology Programme (NTP) studies.

The value of the award to Instem, funded completely by the US government, is approximately $870,000 in the first year, with potential to extend and expand the agreement up to a further nine years, giving a possible total contract value for all 10 years of between $6.2m and $7.6m.

The contract also includes the ability to expand to a larger number of additional sites on the same terms, which could result in a further material increase in revenue, Instem reported.

The NTP is an inter-agency programme designed to coordinate toxicology research and development across the United states Department of Health and Human Services.

The NTP is managed by the NIEHS and supported by the US Food and Drug Administration and the Centers for Disease Control and Prevention.

Phil Reason, Chief Executive Officer of Instem, said: "Such a significant contract with the US government, won through a competitive tendering process, is not only a fantastic endorsement of Instem's innovative software but also of our strategy to support collaborative working practices.

"Our SaaS delivery model enables the sharing of the software between dispersed communities from multiple organisations. The accessibility of Provantis data will also enable the NIEHS to meet a key goal of combining study information with a broader set of biology information to improve scientific insights.

Instem is a supplier of IT applications to the early development healthcare market.

Its share price was up 33.33% to 130p at 12:05 on Thursday.

MF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021
Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
It's not just the UK – we're seeing pandemic housing booms across the globe
Property

It's not just the UK – we're seeing pandemic housing booms across the globe

Soaring house prices aren’t just a UK thing, they’re a worldwide phenomenon. And it’s no coincidence – the underlying cause is much the same. John Ste…
18 Jan 2021